Urnal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Urnal

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Modified-release capsule (Oral preparation)
Pharmacological class Alpha-1 Adrenoceptor Antagonist (Alpha-blocker)
General purpose Functional relief of urinary symptoms
Origin Synthetic compound (Sulfonamide derivative)

Urnal is a prescription-only medication classified as an Alpha-1 Adrenoceptor Antagonist (alpha-blocker). Its primary role is to help provide functional relief for lower urinary tract symptoms, rather than physically curing a condition or shrinking an organ. The drug is defined by its single active component, Tamsulosin Hydrochloride, which is a synthetic compound designed to target specific smooth muscles in the urinary system.


What Type of Medicine is Urnal and What is its Composition?

The active ingredient in Urnal is Tamsulosin Hydrochloride, a compound that belongs to the pharmacological group known as an alpha-blocker. This medication is a synthetic derivative and operates by selectively blocking specific nerve signals that cause muscles to contract. Its targeted action, specifically toward the alpha1A and alpha1D subtypes of adrenoceptors, is used for managing symptoms related to benign prostatic hyperplasia. This selectivity establishes its identity as a precise tool for targeted action in the lower urinary tract.


What is the Form of Urnal and What is its General Purpose?

Urnal is supplied as an oral preparation in the form of a modified-release capsule, intended for systemic action. The general therapeutic purpose of the medication is to achieve smooth muscle relaxation in the prostate gland and the neck of the bladder. The physiological action of Urnal functionally widens the urethral passage, reducing internal resistance. This mechanism results in improved urinary flow, providing symptomatic relief for those experiencing flow issues.


Why is the Modified-Release Formulation Important?

The modified-release capsule is a key feature of Urnal's delivery system, necessary to ensure that the active ingredient is released slowly and consistently into the body over time. This formulation is designed to help maintain a stable, consistent level of Tamsulosin Hydrochloride in the bloodstream. This design supports the necessary sustained physiological effect of muscle relaxation, which is paramount for providing continuous symptomatic relief throughout the day.

Regulatory References

  1. NIH MedlinePlus Tamsulosin

What side effects are possible with Urnal?

Possible Side Effects and Safety Information

The safety profile of Urnal (Tamsulosin Hydrochloride) is characterized by adverse reactions officially classified by incidence and grouped by System-Organ Class. These classifications determine the known risk profile of the medicine.

Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized based on how often they appear in clinical use, according to official regulatory data:

  • Common: Dizziness, Ejaculation disorders (including Retrograde ejaculation and Anosmia).
  • Uncommon: Headache, Palpitations, Postural hypotension, Rhinitis, Constipation, Diarrhoea, Nausea, Vomiting, Rash, Pruritus, Urticaria, Asthenia.
  • Rare: Syncope (fainting), Angioedema (swelling).
  • Very Rare: Priapism, Stevens-Johnson Syndrome (severe skin reaction).

System-Organ Classes and Serious Reactions

The documented effects primarily involve the Nervous System (Dizziness, Headache), Vascular System (Postural hypotension), and Reproductive System (Ejaculation disorders). The rare reactions, Angioedema, Priapism, and Stevens-Johnson Syndrome, are officially designated as serious adverse reactions.

Safety Considerations and Restrictions

The risk of Postural Dizziness and Postural Hypotension is officially noted to be more common at the start of treatment and during any subsequent dose increase. Urnal is formally restricted and should not be used in individuals with a known history of symptomatic Orthostatic Hypotension. Caution is also advised regarding use in patients with severe renal impairment and severe hepatic impairment.

Furthermore, an association with Intraoperative Floppy Iris Syndrome (IFIS) is noted for patients undergoing Cataract or Glaucoma Surgery, a specific consideration documented in the medicine's official safety profile.

Overdose and Emergency Response

Urnal Overdose and When to Seek Help

Overdose of Urnal (Tamsulosin Hydrochloride) is officially documented to present with severe hypotensive effects, leading to a sudden, significant drop in blood pressure. Other manifestations cited in regulatory summaries include vomiting and diarrhoea. The primary physiological system affected is the cardiovascular system, which may require specialized support. Procedures such as gastric lavage and activated charcoal are specified for situations involving the ingestion of large quantities.

Regulators mandate that patients must seek immediate medical attention for a suspected overdose. Urgent medical help is required immediately if the individual experiences collapse, seizure, trouble breathing, or cannot be awakened. The immediate physical intervention is to place the patient in the supine position to help restore blood pressure. If this is insufficient, cardiovascular support, including the employment of volume expanders or vasopressors, may be necessary.

The official management strategy mandates that renal function should be monitored as a required observation measure. Furthermore, regulatory context constraints confirm that dialysis is unlikely to be of help due to the high plasma protein binding of the active ingredient. The overdose profile is thus defined by managing the resulting severe hypotensive crisis.

Therapeutic Uses of Urnal

What Urnal treats: main uses and benefits

Urnal is a pharmacological treatment primarily indicated for the management of lower urinary tract symptoms associated with certain urological conditions. Its active components work to address functional imbalances in the urinary system, specifically focusing on the muscles of the bladder and the prostate.

Main Therapeutic Uses

The primary application of Urnal is in the treatment of symptoms related to benign prostatic hyperplasia (BPH). In this condition, the enlargement of the prostate gland can lead to mechanical and dynamic obstruction of the urethra, resulting in various voiding difficulties. Urnal helps by:

  • Improving urinary flow: By relaxing the smooth muscles in the prostate and the bladder neck, it reduces resistance to urine flow.
  • Reducing frequency and urgency: It helps stabilize bladder activity, decreasing the sudden, compelling need to urinate and the overall frequency of bathroom visits, particularly during the night.
  • Managing incomplete emptying: It assists in more effective bladder voiding, which can reduce the sensation of residual urine after urination.

Functional Benefits

The clinical benefit of Urnal lies in its ability to target the physiological mechanisms that cause urinary discomfort. By facilitating the relaxation of specific muscle tissues without compromising the overall contractile ability of the bladder, it allows for a more controlled and comfortable urinary process.

Patients prescribed Urnal typically observe a gradual improvement in the quality of their urinary function. The medication focuses on symptom relief and the stabilization of lower urinary tract dynamics, which contributes to an overall reduction in the daily impact of urological obstructions.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Urnal (Tamsulosin Hydrochloride) is officially approved for use exclusively in adult males for its indicated purpose. Regulatory agencies strictly define the populations eligible to use this medication.

Populations Not Eligible for Urnal

Urnal is formally contraindicated and must not be used in the following populations:

  • Patients with a documented hypersensitivity to Tamsulosin Hydrochloride or any component of the medication.
  • Individuals with a history of orthostatic hypotension (a drop in blood pressure when standing).
  • Patients with severe hepatic insufficiency (severe liver impairment).

Age and Sex Restrictions

Use is not indicated for women, which includes patients who are pregnant or breastfeeding, as the drug's approved indication is specific to men. Furthermore, use is not recommended in children and adolescents under 18 years of age, as the safety and efficacy have not been established in the pediatric population.

Conditions Requiring Caution or Restriction

Caution is warranted for patients with a severe sulfa allergy, given the drug’s chemical derivation. Initiation of therapy is not recommended for patients scheduled for cataract or glaucoma surgery due to the associated risk of a documented complication. While no dose adjustment is required for mild to moderate renal or hepatic impairment, use in end-stage renal disease has not been studied.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions documented in official regulatory labeling (e.g., FDA, EMA) and is not intended as medical advice.

Pharmacokinetic Interactions

Urnal is a substrate for the metabolic enzyme CYP3A4 and the efflux transporter P-glycoprotein (P-gp). This characteristic dictates its major drug interaction profile.

  • Contraindicated Combinations: Co-administration with potent CYP3A4 inducers, such as rifampin or phenytoin, is contraindicated. These agents significantly decrease Urnal's plasma exposure, leading to a loss of therapeutic effect.
  • Exposure Increases: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) or P-gp inhibitors (e.g., cyclosporine) substantially increases Urnal's plasma concentrations (AUC and Cmax). This requires careful management as detailed in the drug's labeling.

Pharmacodynamic and Non-Drug Interactions

Interactions can also occur through combined physiological effects or with non-prescription items.

  • Additive Effects: Using Urnal concurrently with other CNS depressants (e.g., opioids) can lead to an additive increase in CNS depression.
  • Food and Supplements: Administration with a high-fat meal is documented to increase Urnal's bioavailability. Concomitant use with the herbal product St. John's Wort is strongly discouraged due to its potent CYP3A4-inducing properties.

Mechanism of Action

Urnal functions as an inhibitor of the enzyme xanthine oxidase. This enzyme is a critical component in the purine catabolism pathway, catalyzing the conversion of hypoxanthine to xanthine, and subsequently the conversion of xanthine to uric acid. Upon systemic absorption, Urnal undergoes hepatic metabolism to form its primary, long-acting active metabolite, oxypurinol. Both Urnal and oxypurinol act as non-competitive inhibitors at the active site of xanthine oxidase, forming a tightly bound enzyme-inhibitor complex. This molecular interaction reduces the enzymatic turnover rate. The resulting intracellular pathway consequence is a decrease in the biosynthesis of uric acid in the hepatocyte and other tissues. This diminished uric acid production leads to a subsequent decrease in the concentration of uric acid within the systemic circulation and the urinary tract, facilitating system-level modulation of purine waste product concentrations.

Dosage and Administration Information

How Urnal is Used

Urnal is a prescription-only medication for oral administration that adheres to specific guidance regarding its intake schedule. The medication is supplied as a modified-release capsule, which is designed to provide a sustained, consistent release of the active ingredient over a 24-hour period.


Administration Schedule

Category Instruction
Route of Administration Oral use, swallowed by mouth.
Standard Schedule Taken once daily.
Timing Relative to Food Must be taken approximately one-half hour following the same meal each day (e.g., after breakfast).

Procedural and Population Requirements

The prolonged-release capsule is structurally designed to release the component over time, making it mandatory that the capsule must be swallowed whole and should not be crushed, chewed, or opened. Violating this requirement compromises the modified-release profile.

For most adult patients, a standard once-daily routine is maintained. In instances where use is temporarily interrupted for several days, the process typically involves returning to the initial starting routine, regardless of the previous schedule. Furthermore, documented clinical parameters generally indicate that no adjustment is necessary for individuals with mild to severe renal impairment or mild to moderate hepatic impairment, and the medication is not indicated for use in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urnal

Evidence for Use in Lower Urinary Tract Symptoms (LUTS) Suggestive of BPH

The primary research exploring Urnal's active ingredient in men with LUTS associated with BPH involves short-term randomized, controlled trials (RCTs), typically lasting about three months, where the active component was compared against an inactive placebo. These studies applied standardized patient-reported outcome scores and measured objective flow parameters, such as maximum urinary flow rate (Q max). The evidence derived from these settings describes patterns related to how symptoms changed in the observed populations during the study period. While research describes these short-term changes, evidence suggests that the magnitude of change reported for objective flow rate measurements was noted as sometimes variable across different reports.

Research Landscape for Other Populations and Long-Term Data

Research has also explored whether Urnal's active ingredient could be studied in adult women presenting with LUTS, but systematic reviews indicate that findings in this population were mixed and the available evidence is limited in scope and volume. For long-term follow-up, studies relied mainly on non-blinded, open-label extension studies, which monitored patients for several years after the initial placebo-controlled trials concluded. This long-term evidence contributes to understanding the continuation of treatment but, due to the lack of a concurrent placebo group, comparative certainty regarding the maintenance of change is reduced.

Key Gaps and Areas of Uncertainty

The available research highlights that certainty remains low regarding very long-term patterns, as the gold-standard placebo-controlled research only spanned a short duration. Data for certain groups, such as specific combinations of multiple medical conditions, remain insufficient. Furthermore, the objective flow rate measurements showed heterogeneity across findings, suggesting that study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Urnal (FAQ)

Q: Does Urnal have any major known interactions with common over-the-counter pain relievers?

A: Official drug interaction studies listed in regulatory documents focus on how Urnal interacts with specific prescription medications and certain enzyme inhibitors. The official label does not specifically address all common over-the-counter pain relievers. The patient labeling contains a complete list of known interactions.

Q: Why does the packaging for Urnal have a specific warning about [broad condition]?

A: Official warnings are included on the packaging because clinical studies or post-marketing surveillance identified specific risks associated with the drug. For instance, severe warnings address risks like orthostatic hypotension (a drop in blood pressure upon standing) or the rare risk of priapism, which were observed in patients taking the medication. These statements reflect documented risks in the official safety profile.

Q: Is it normal to feel [general symptom like tired/dizzy] when first starting Urnal?

A: Dizziness is listed in the official documents as a common adverse reaction to Urnal. The risk of dizziness and low blood pressure upon standing (postural hypotension) is noted to be greater when treatment is first started or when the dose is increased. Official information also lists somnolence (drowsiness) as another associated side effect.

Q: Can Urnal be taken with vitamins or herbal supplements?

A: Regulatory information specifically warns against taking Urnal with the herbal product St. John's Wort due to the risk of a serious drug interaction that can reduce Urnal’s effectiveness. General guidance on common vitamins and most other specific supplements is not detailed in the official product information.

Q: What are the long-term effects of taking Urnal?

A: The official safety profile is established through short-term clinical trials and longer-term open-label studies that monitored patients for several years. All adverse reactions, regardless of how long the patient took the drug, are categorized and listed in the official label. The known risk profile is determined by these documented effects.

Q: Does Urnal affect mental clarity or concentration?

A: Official information lists adverse reactions that affect the nervous system, such as dizziness, headache, and drowsiness (somnolence). The occurrence of these effects is documented in the safety profile and can impact a patient's alertness.

Q: What are the signs of a serious allergic reaction to Urnal?

A: Signs of a severe hypersensitivity reaction, such as those officially classified as rare or very rare, may include a severe skin rash, hives, or generalized swelling (angioedema). The product label lists these reactions as serious potential side effects. Emergency medical attention should be sought immediately if these reactions occur.

Q: Can Urnal affect fertility in men or women?

A: Urnal is approved only for use in adult males and is not indicated for women. Official documents commonly list ejaculation disorders, including a decrease in semen (retrograde ejaculation), as a common adverse reaction in men.

Q: Can I drive or operate machinery while taking Urnal?

A: Official patient counseling information advises caution regarding driving or performing hazardous tasks. This is because the medication is associated with dizziness and fainting (syncope), which may increase the risk of accidental injury during these activities.

Q: How long does it typically take for Urnal to start working?

A: In clinical studies, the initial effectiveness of the drug is generally assessed after two to four weeks of treatment. This period allows time for the sustained-release mechanism of the capsule to establish a consistent effect before any consideration for a dose change.

Q: If I miss a dose of Urnal, what generally happens?

A: If a single dose is missed, official patient information generally indicates the dose should be skipped, followed by a return to the regular dosing schedule. If treatment has been stopped for several consecutive days, regulatory instruction dictates that therapy must be restarted at the lowest initial dose.

Q: Is Urnal safe for use in older adults?

A: Official documents, including the Geriatric Use section of the label, indicate that no dosage adjustment is necessary for elderly patients aged 65 and older. The safety and efficacy of the drug have been studied in this population.

Q: Can Urnal affect sleep patterns?

A: The adverse reactions listed in the official clinical trial data include reports of both insomnia (difficulty falling or staying asleep) and somnolence (drowsiness). These effects are categorized under nervous system disorders.

Q: What should I do if I notice a change in my [bodily function, e.g., urination] while on Urnal?

A: Official patient counseling information includes a recommendation to monitor the signs and symptoms of your condition during the treatment period. Additionally, official guidelines recommend routine screenings for prostate cancer prior to starting the medication and periodically thereafter.

Q: What happens if I accidentally take too much Urnal?

A: The official overdosage section states that taking too much Urnal may result in hypotension, or abnormally low blood pressure. The first official step noted for overdosage management is typically support of the cardiovascular system, which may involve keeping the individual in a lying-down position.

Q: How does Urnal interact with common allergy medications?

A: Specific allergy medications are not uniformly listed in the regulatory label’s primary interaction sections. However, official information notes that caution is warranted when the drug is used alongside other medications that block alpha-adrenergic signals or inhibit the CYP2D6 enzyme, as some allergy medications may fall into these categories.

Q: Are there any documented cases of addiction or dependency with Urnal?

A: Official labeling, in the section concerning Drug Abuse and Dependence, explicitly states that the medication has not been associated with abuse potential or withdrawal symptoms when stopped.

Q: Where can I find the official patient information leaflet for Urnal?

A: The complete, official patient labeling, which includes the Patient Information or Medication Guide, is available through government resources like the FDA's approved databases. These documents provide all detailed information about the drug for patients.

Q: Is there any difference in how Urnal works for different people?

A: Studies on the body's processing of the drug show that drug exposure can be significantly higher in patients who are known to be poor metabolizers of the CYP2D6 enzyme. This difference in how the body processes the medication may lead to a varied response compared to patients with typical metabolism.

Q: Does Urnal interact with grapefruit juice?

A: Urnal is processed by the CYP3A4 enzyme, and official labels document interactions with strong CYP3A4 inhibitors like ketoconazole. While grapefruit juice is a known enzyme inhibitor, it is not explicitly listed in the major interaction sections of the official product labeling.

Q: Is Urnal classified as a controlled substance?

A: Official documentation confirms that Urnal is not classified as a controlled substance by the DEA or other regulatory bodies.

Q: How is the safety of Urnal monitored after it is approved?

A: After the drug is approved and available to the public, its safety continues to be monitored through post-marketing surveillance. This is a process where adverse reactions that occur during clinical use are reported voluntarily by patients and healthcare providers, and the information is tracked by regulatory bodies.

Q: How does alcohol affect the use of Urnal?

A: Official information indicates that alcohol can lower blood pressure. Since Urnal is associated with a risk of orthostatic hypotension (low blood pressure when standing up), consuming alcohol while taking the medication may increase this risk, potentially leading to symptoms such as lightheadedness or dizziness.

How should Urnal be stored and disposed of?

How to Store and Dispose of Urnal?

Properly storing and disposing of Urnal is essential for safety, especially since it is a controlled substance. Generally, medications should be kept in a secure area, away from heat and moisture, and out of the reach of children. Specifically, Urnal, if classified as a controlled substance, must be stored in a securely locked cabinet or drawer to prevent misuse and diversion, as required by regulatory bodies like the FDA and DEA.

Containers for dispensed medication should always be child-proof. Regarding disposal, the best method is utilizing a formal drug take-back program available through pharmacies or local law enforcement. If a take-back option is unavailable, you may be instructed to mix the medicine with an unappealing substance, such as coffee grounds, place it in a sealed container, and dispose of it in the household trash, after scratching out all personal information on the label. Never flush medication unless it is specifically on the FDA's flush list for highly potent and dangerous drugs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Urnal found in:

A-Z Index: